Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Allergen reduction by nightly temperature controlled laminar airflow (TLA) decreases exacerbation rate in severe allergic asthma

Allergen reduction by nightly temperature controlled laminar airflow (TLA) decreases exacerbation... Schauer and Hamelmann Clinical and Translational Allergy 2015, 5(Suppl 2):O5 http://www.ctajournal.com/content/5/S2/O5 ORAL PRESENTATION Open Access Allergen reduction by nightly temperature controlled laminar airflow (TLA) decreases exacerbation rate in severe allergic asthma 1* 2 Uwe Schauer , Eckard Hamelmann From 2nd International Severe Asthma Forum (ISAF) Athens, Greece. 13-15 November 2014 Introduction utilization of hospital resources at disease deteriorations. It has earlier been shown that TLA significantly reduces Higher proportions of patients with increased control of allergen exposure and airway inflammation and improves asthma symptoms were also observed. The data demon- quality of life in poorly controlled allergic asthma patients. strate that TLA may be an important new approach in the treatment of poorly controlled allergic asthma Aim and objective patients. The primary aim was to evaluate real-life effects of TLA (Airsonett AB) when used during night-time for 12 con- Authors’ details secutive months as add on to the patients ’ regular 1 2 Ruhr Universität Bochum, Universitäts-Kinderklinik, Bochum, Germany. Ruhr medication. Universität Bochum, Allergie Centrum, Bochum, Germany. Published: 23 March 2015 Methods The study compared pre- versus post-TLA initiation data from patients with poorly controlled severe persis- doi:10.1186/2045-7022-5-S2-O5 tent allergic asthma. Outcome parameters were collected Cite this article as: Schauer and Hamelmann: Allergen reduction by at four and 12 months on medication use, asthma con- nightly temperature controlled laminar airflow (TLA) decreases exacerbation rate in severe allergic asthma. Clinical and Translational trol, asthma symptoms, lung function, rate and use of Allergy 2015 5(Suppl 2):O5. hospital resources due to exacerbations were collected. Results Data from 30 patients (mean age 28; range 8-70) complet- ing 4 months and 27 patients completing 12 months of TLA use, are presented. Ratios (%) or means (range) At baseline After 12 months of TLA P-value Exacerbations Submit your next manuscript to BioMed Central last 12 months3.6 (0-12)1.3 (0-5)0.05Asthma Control and take full advantage of: Test14.1 (5-27)18.5 (8-27)<0.001Ratio with uncontrolled disease, GINA55.20<0.001Ratio with controlled disease, • Convenient online submission GINA10.333.3 • Thorough peer review • No space constraints or color figure charges Conclusion • Immediate publication on acceptance The addition of TLA to the patients’ regular medication • Inclusion in PubMed, CAS, Scopus and Google Scholar significantly reduced the risk of exacerbations and the • Research which is freely available for redistribution Submit your manuscript at Ruhr Universität Bochum, Universitäts-Kinderklinik, Bochum, Germany www.biomedcentral.com/submit Full list of author information is available at the end of the article © 2015 Schauer and Hamelmann; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Translational Allergy Springer Journals

Allergen reduction by nightly temperature controlled laminar airflow (TLA) decreases exacerbation rate in severe allergic asthma

Download PDF
1 page

Loading next page...
 
/lp/springer-journals/allergen-reduction-by-nightly-temperature-controlled-laminar-airflow-IEbe0AoA9B

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2015 by Schauer and Hamelmann; licensee BioMed Central Ltd.
Subject
Medicine & Public Health; Allergology; Immunology
eISSN
2045-7022
DOI
10.1186/2045-7022-5-S2-O5
Publisher site
See Article on Publisher Site

Abstract

Schauer and Hamelmann Clinical and Translational Allergy 2015, 5(Suppl 2):O5 http://www.ctajournal.com/content/5/S2/O5 ORAL PRESENTATION Open Access Allergen reduction by nightly temperature controlled laminar airflow (TLA) decreases exacerbation rate in severe allergic asthma 1* 2 Uwe Schauer , Eckard Hamelmann From 2nd International Severe Asthma Forum (ISAF) Athens, Greece. 13-15 November 2014 Introduction utilization of hospital resources at disease deteriorations. It has earlier been shown that TLA significantly reduces Higher proportions of patients with increased control of allergen exposure and airway inflammation and improves asthma symptoms were also observed. The data demon- quality of life in poorly controlled allergic asthma patients. strate that TLA may be an important new approach in the treatment of poorly controlled allergic asthma Aim and objective patients. The primary aim was to evaluate real-life effects of TLA (Airsonett AB) when used during night-time for 12 con- Authors’ details secutive months as add on to the patients ’ regular 1 2 Ruhr Universität Bochum, Universitäts-Kinderklinik, Bochum, Germany. Ruhr medication. Universität Bochum, Allergie Centrum, Bochum, Germany. Published: 23 March 2015 Methods The study compared pre- versus post-TLA initiation data from patients with poorly controlled severe persis- doi:10.1186/2045-7022-5-S2-O5 tent allergic asthma. Outcome parameters were collected Cite this article as: Schauer and Hamelmann: Allergen reduction by at four and 12 months on medication use, asthma con- nightly temperature controlled laminar airflow (TLA) decreases exacerbation rate in severe allergic asthma. Clinical and Translational trol, asthma symptoms, lung function, rate and use of Allergy 2015 5(Suppl 2):O5. hospital resources due to exacerbations were collected. Results Data from 30 patients (mean age 28; range 8-70) complet- ing 4 months and 27 patients completing 12 months of TLA use, are presented. Ratios (%) or means (range) At baseline After 12 months of TLA P-value Exacerbations Submit your next manuscript to BioMed Central last 12 months3.6 (0-12)1.3 (0-5)0.05Asthma Control and take full advantage of: Test14.1 (5-27)18.5 (8-27)<0.001Ratio with uncontrolled disease, GINA55.20<0.001Ratio with controlled disease, • Convenient online submission GINA10.333.3 • Thorough peer review • No space constraints or color figure charges Conclusion • Immediate publication on acceptance The addition of TLA to the patients’ regular medication • Inclusion in PubMed, CAS, Scopus and Google Scholar significantly reduced the risk of exacerbations and the • Research which is freely available for redistribution Submit your manuscript at Ruhr Universität Bochum, Universitäts-Kinderklinik, Bochum, Germany www.biomedcentral.com/submit Full list of author information is available at the end of the article © 2015 Schauer and Hamelmann; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Journal

Clinical and Translational Allergy – Springer Journals

Published: Mar 23, 2015

There are no references for this article.